# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments fo...
Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024Key Proof-of-Concept Resu...
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...
Craig-Hallum analyst Alexander Nowak assumes DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy rating and announces Price Targ...
Craig-Hallum analyst Alexander Nowak maintains DiaMedica Therapeutics (NASDAQ:DMAC) with a Buy and lowers the price target f...
Oppenheimer analyst Francois Brisebois reiterates DiaMedica Therapeutics (NASDAQ:DMAC) with a Outperform and lowers the pric...
Financial ResultsResearch and development (R&D) expenses increased to $13.1 million for the year ended December 31, 2023, u...